PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Inclusion Criteria: 1. Age and Gender: ≥18 years old (inclusive), regardless of gender. 2. Survival Expectancy: ≥3 months. 3. Performance Status: ECOG score 0-1. 4. Diagnosis: Confirmed acute T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) according to the WHO fifth edition of the "Classification of Hematopoietic and Lymphoid Tumors," including early T-cell precursor (ETP). 5. Recurrent or Refractory Disease: Subjects with recurrent/refractory T-ALL/LBL (including ETP-ALL/LBL). 6. Screening: Abnormal cells CD7 expression positive. 7. Lesion Assessment: If the subject has only extramedullary lesions, they must have evaluable lesions. 8. Meet the requirements of liver, kidney, heart, and lung functions. 9. No Severe Mental Disorders. 10. Informed Consent: Ability to understand the trial and signed informed consent form. Exclusion Criteria: 1. Known to have active or uncontrolled autoimmune diseases; 2. Presence of GvHD; 3. History of malignant tumors other than T-ALL/LBL within the past 5 years, except for adequately treated cervical intraepithelial neoplasia, basal cell or squamous cell skin cancer, locally treated prostate cancer, and ductal carcinoma in situ of the breast after radical surgery; 4. Positive test results for hepatitis B, hepatitis C, syphilis, etc.; 5. Severe heart disease; 6. Unstable systemic diseases as judged by the investigator; 7. Presence of active infection or uncontrollable infection requiring systemic treatment; 8. Pregnant or breastfeeding women, and female subjects planning to conceive within 2 years after cell infusion, or male subjects whose partners plan to conceive within 2 years after cell infusion; 9. Subjects who have received CAR-T therapy or other gene-modified cell therapy before screening; 10. Participation in other clinical studies within 1 month before screening (end date of the last application of unapproved innovative drugs); 11. Evidence of central nervous system involvement at the time of subject screening; 12. Situations judged by the investigator as not suitable for cell preparation; 13. Other circumstances deemed unsuitable for enrollment by the investigator.